Calidi BiotherapeuticsCLDI
About: Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
Employees: 28
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
260% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 5
249% more capital invested
Capital invested by funds: $363K [Q3] → $1.27M (+$903K) [Q4]
65% more funds holding
Funds holding: 20 [Q3] → 33 (+13) [Q4]
1.9% more ownership
Funds ownership: 3.95% [Q3] → 5.85% (+1.9%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for CLDI.
Financial journalist opinion









